- Home
- STOK vs PNNT Comparison
STOK vs PNNT Comparison
Compare STOK & PNNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STOK
- PNNT
- Stock Information
- Founded
- STOK 2014
- PNNT 2007
- Country
- STOK United States
- PNNT United States
- Employees
- STOK N/A
- PNNT N/A
- Industry
- STOK Biotechnology: Pharmaceutical Preparations
- PNNT Finance: Consumer Services
- Sector
- STOK Health Care
- PNNT Finance
- Exchange
- STOK Nasdaq
- PNNT Nasdaq
- Market Cap
- STOK 556.7M
- PNNT 459.4M
- IPO Year
- STOK 2019
- PNNT 2007
- Fundamental
- Price
- STOK $8.33
- PNNT $7.17
- Analyst Decision
- STOK Strong Buy
- PNNT Hold
- Analyst Count
- STOK 8
- PNNT 2
- Target Price
- STOK $23.83
- PNNT $6.00
- AVG Volume (30 Days)
- STOK 830.1K
- PNNT 436.5K
- Earning Date
- STOK 03-24-2025
- PNNT 02-10-2025
- Dividend Yield
- STOK N/A
- PNNT 12.97%
- EPS Growth
- STOK N/A
- PNNT 11.30
- EPS
- STOK N/A
- PNNT 0.83
- Revenue
- STOK $16,742,999.00
- PNNT $143,689,000.00
- Revenue This Year
- STOK $105.42
- PNNT N/A
- Revenue Next Year
- STOK $15.13
- PNNT N/A
- P/E Ratio
- STOK N/A
- PNNT $8.62
- Revenue Growth
- STOK 81.08
- PNNT N/A
- 52 Week Low
- STOK $5.28
- PNNT $6.43
- 52 Week High
- STOK $17.58
- PNNT $8.04
- Technical
- Relative Strength Index (RSI)
- STOK 32.00
- PNNT 54.56
- Support Level
- STOK $9.76
- PNNT $7.10
- Resistance Level
- STOK $11.11
- PNNT $7.25
- Average True Range (ATR)
- STOK 0.88
- PNNT 0.09
- MACD
- STOK -0.30
- PNNT 0.00
- Stochastic Oscillator
- STOK 2.31
- PNNT 70.69
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
About PNNT PennantPark Investment Corporation
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.